Core Insights - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiqi Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China [1][2] - The collaboration will leverage JD Health's strengths in medical services and instant retail, launching two innovative drugs: the first-class drug Adefovir Dipivoxil Tablets (brand name: Xinshumu®) and a zinc-selenium multivitamin soft capsule (brand name: Kaimumu®) [1][2] Drug Launch Details - Adefovir Dipivoxil Tablets (Xinshumu®) are designed for the treatment of adult chronic hepatitis B and have received support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans [1] - Clinical trial results indicate that the drug effectively and persistently inhibits the virus, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) and other similar drugs [1] - The zinc-selenium multivitamin soft capsule (Kaimumu®) is formulated for liver nutrition and is rich in nine vitamins and two minerals, designed for easy absorption and convenient daily use [2] Service Integration - JD Health will utilize its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a service loop that includes professional supply, online specialist guidance, and rapid delivery, facilitating the widespread availability of the new drugs [2] - Patients can purchase these new drugs through the JD APP or JD pharmacies nationwide with a valid prescription starting immediately [2] Strategic Goals - JD Health aims to enhance the overall efficiency and quality of the pharmaceutical supply chain through ongoing strategic collaboration with Kaiqi Xincheng, optimizing the patient experience [2] - The company is committed to providing high-quality pharmaceutical health products and services, contributing to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs [3]

Core Viewpoint - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China through integrated resources in medical services and instant retail [1][2]. Group 1: Product Launch and Features - JD Health and Kaiji Xincheng have launched the first-class innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu), which targets chronic hepatitis B treatment using HepDirectTM liver-targeting technology [1]. - The drug has received significant support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans, demonstrating its efficacy in delivering active ingredients directly to the liver, enhancing effectiveness while reducing toxicity [1]. - Phase III clinical trial results indicate that the drug shows stronger and more durable viral suppression compared to the control group, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL (P<0.05) [1]. Group 2: Nutritional Supplement - The Zinc-Selenium Multivitamin Soft Gel Capsules (brand name: Kaimumu) are designed for liver nutrition and suitable for individuals needing supplementation of zinc, selenium, and various vitamins [2]. - This product contains nine vitamins and two minerals, scientifically proportioned and packaged in soybean lecithin capsules for better absorption, with a recommended dosage of two capsules daily [2]. Group 3: Service Integration and Strategy - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to provide a comprehensive service loop, ensuring rapid dissemination of the new drugs to patients [2]. - The collaboration aims to optimize the overall patient service experience and enhance the efficiency and quality of the pharmaceutical supply chain, promoting a win-win development [2]. - JD Health is committed to providing high-quality pharmaceutical health products and services, enhancing the accessibility of innovative drugs to a broader patient population [2][3]. Group 4: Future Outlook - JD Health's value effect as the "first station for new special drug launches" continues to expand, facilitating access to cutting-edge innovative drugs through integrated online and offline channels [3]. - The company plans to collaborate with global pharmaceutical partners to improve the accessibility of new special drugs, contributing to the "Healthy China 2030" strategic goals [3].

Core Viewpoint - JD Health has entered into a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to enhance the treatment options for chronic hepatitis B patients in China [1][2]. Group 1: Partnership and Product Launch - The collaboration aims to integrate JD Health's strengths in medical services and instant retail to support clinical cure goals for chronic hepatitis B patients [1]. - The first launch of the innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu®), and Zinc-Selenium Multivitamin Soft Capsules (brand name: Kaimumu®) will be exclusive to JD Health's platform [1][2]. - Mesylate Prefofovir Tablets are designed for adult chronic hepatitis B treatment and have received significant support from national major new drug creation technology projects [1]. Group 2: Clinical Efficacy and Product Features - Phase III clinical trial results indicate that the drug effectively suppresses the virus more powerfully and durably, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) [1]. - The Zinc-Selenium Multivitamin Soft Capsules are formulated to support liver health and are rich in various vitamins and minerals, designed for easy absorption [2]. Group 3: Service Integration and Future Plans - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a comprehensive service loop for the new drugs, ensuring rapid accessibility for patients [2]. - The company plans to continue deepening strategic collaboration with Kaiji Xincheng to optimize patient service experiences and enhance the overall efficiency and quality of the pharmaceutical supply chain [2][3]. - JD Health aims to contribute to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs through partnerships with global pharmaceutical companies [3].